Transcatheter and Surgical Aortic Valve Replacement Compared for Severe Stenosis in an All-Comers Trial

No difference in death, stroke, or myocardial infarction was found at 1 year in this randomized trial of patients at low surgical risk.

To compare outcomes with surgical versus transcatheter treatment of severe aortic stenosis in patients at low surgical risk, researchers conducted a randomized trial at three Nordic centers in 280 patients aged >70 years (mean age, 79 years; 53% male) with severe aortic stenosis. Patients were randomly assigned to treatment with a self-expanding transcatheter aortic valve replacement (TAVR) prosthesis or open surgery (SAVR). The mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 3.0, and 82% were considered low-risk (score <4). Several of the authors are either employees of the TAVR prosthesis manufacturer or report receiving speaker fees or contracts from one of the prosthesis manufacturers.

The primary outcome of death…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)